Related Experiment Video
Updated: May 8, 2026
An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
Evaluation of inhibitor antibody in hemophiliaA population
Hassan Mahmoodi Nesheli1, Amereh Hadizadeh, Ali Bijani
1Non- Communicable Pediatrics Diseases Research Center, Babol University of Medical Sciences, Babol, Iran.
Background:
Inhibitor antibody to exogenous Factor VIII (FVIII) is a major complication of hemophilia treatment. This study was conducted to determine the prevalence of inhibitor antibody directed against FVIII.
Methods:
From May 2010 to May 2011, 52 patients with severe hemophilia A admitted in Amirkola Children's Hospital were evaluated. Those who had abnormal mixing study, antibody against FVIII were measured. Data were collected and analyzed.
Results:
The age range of the patients was 4-60 years. The inhibitor antibody was seen in 9 (17.3%) patients. The mean age of patients with inhibitor at the time of diagnosis was 10.22 years (ranged 4-31 years). Old patients had more hemarthrosis than young patients. The mean level of inhibitor antibody was 8.47 Bethesda unit (ranged 2.3-29). Six patients had inhibitor antibody level ≥5 Bethesda unit and three patients had inhibitor antibody level <5 Bethesda unit.
Conclusion:
This study showed that the prevalence of inhibitor antibodies in young patients is more than the old patients.
